Besides significantly prolonging the life of premenopausal patients with advanced breast cancer, improving their quality of life, workforce retention due to ribociclib yields economic productivity gains to society, thus supporting its use combined with endocrine therapy for premenopausal women with HR+/HER2- metastatic breast disease. This evidence concerns the gene HR and breast cancer.